[{"words": [{"word": "业绩", "head": 2, "tag": "n", "deprels": "SBV", "no": 0}, {"word": "修正", "head": 3, "tag": "v", "deprels": "ATT", "no": 1}, {"word": "原因", "head": 4, "tag": "n", "deprels": "SBV", "no": 2}, {"word": "说明", "head": 0, "tag": "v", "deprels": "HED", "no": 3}, {"word": "根据", "head": 10, "tag": "p", "deprels": "ADV", "no": 4}, {"word": "《", "head": 9, "tag": "wp", "deprels": "WP", "no": 5}, {"word": "企业", "head": 9, "tag": "n", "deprels": "ATT", "no": 6}, {"word": "会计", "head": 9, "tag": "n", "deprels": "ATT", "no": 7}, {"word": "准则", "head": 5, "tag": "n", "deprels": "POB", "no": 8}, {"word": "解释", "head": 4, "tag": "v", "deprels": "VOB", "no": 9}, {"word": "第4", "head": 12, "tag": "m", "deprels": "ATT", "no": 10}, {"word": "号", "head": 10, "tag": "q", "deprels": "VOB", "no": 11}, {"word": "》", "head": 12, "tag": "wp", "deprels": "WP", "no": 12}, {"word": "，", "head": 10, "tag": "wp", "deprels": "WP", "no": 13}, {"word": "公司", "head": 20, "tag": "n", "deprels": "SBV", "no": 14}, {"word": "通过", "head": 20, "tag": "p", "deprels": "ADV", "no": 15}, {"word": "多次", "head": 18, "tag": "m", "deprels": "ADV", "no": 16}, {"word": "交易", "head": 16, "tag": "v", "deprels": "POB", "no": 17}, {"word": "，", "head": 16, "tag": "wp", "deprels": "WP", "no": 18}, {"word": "实现", "head": 10, "tag": "v", "deprels": "COO", "no": 19}, {"word": "对", "head": 47, "tag": "p", "deprels": "ADV", "no": 20}, {"word": "非同一", "head": 27, "tag": "b", "deprels": "ATT", "no": 21}, {"word": "控制", "head": 27, "tag": "v", "deprels": "ATT", "no": 22}, {"word": "下", "head": 23, "tag": "nd", "deprels": "CMP", "no": 23}, {"word": "的", "head": 23, "tag": "u", "deprels": "RAD", "no": 24}, {"word": "联营", "head": 27, "tag": "v", "deprels": "ATT", "no": 25}, {"word": "企业", "head": 31, "tag": "n", "deprels": "SBV", "no": 26}, {"word": "1", "head": 31, "tag": "m", "deprels": "ADV", "no": 27}, {"word": "广东", "head": 30, "tag": "ns", "deprels": "ATT", "no": 28}, {"word": "嘉应", "head": 28, "tag": "nz", "deprels": "COO", "no": 29}, {"word": "制药", "head": 21, "tag": "v", "deprels": "POB", "no": 30}, {"word": "股份", "head": 33, "tag": "n", "deprels": "ATT", "no": 31}, {"word": "有限公司", "head": 35, "tag": "n", "deprels": "ATT", "no": 32}, {"word": "2013", "head": 35, "tag": "m", "deprels": "ATT", "no": 33}, {"word": "年度", "head": 36, "tag": "n", "deprels": "ATT", "no": 34}, {"word": "业绩", "head": 31, "tag": "n", "deprels": "VOB", "no": 35}, {"word": "预告", "head": 31, "tag": "v", "deprels": "COO", "no": 36}, {"word": "修正", "head": 39, "tag": "v", "deprels": "ATT", "no": 37}, {"word": "公告", "head": 45, "tag": "n", "deprels": "ATT", "no": 38}, {"word": "湖南", "head": 45, "tag": "ns", "deprels": "ATT", "no": 39}, {"word": "金沙", "head": 45, "tag": "nz", "deprels": "ATT", "no": 40}, {"word": "药业", "head": 45, "tag": "n", "deprels": "ATT", "no": 41}, {"word": "有限", "head": 44, "tag": "a", "deprels": "ATT", "no": 42}, {"word": "责任", "head": 45, "tag": "n", "deprels": "ATT", "no": 43}, {"word": "公司", "head": 37, "tag": "n", "deprels": "VOB", "no": 44}, {"word": "的", "head": 31, "tag": "u", "deprels": "RAD", "no": 45}, {"word": "合并", "head": 20, "tag": "v", "deprels": "VOB", "no": 46}, {"word": "，", "head": 10, "tag": "wp", "deprels": "WP", "no": 47}, {"word": "在", "head": 73, "tag": "p", "deprels": "ADV", "no": 48}, {"word": "合并", "head": 51, "tag": "v", "deprels": "ATT", "no": 49}, {"word": "报表", "head": 52, "tag": "n", "deprels": "ATT", "no": 50}, {"word": "中", "head": 49, "tag": "nd", "deprels": "POB", "no": 51}, {"word": "，", "head": 49, "tag": "wp", "deprels": "WP", "no": 52}, {"word": "对", "head": 73, "tag": "p", "deprels": "ADV", "no": 53}, {"word": "购买日", "head": 56, "tag": "n", "deprels": "ATT", "no": 54}, {"word": "之前", "head": 57, "tag": "nd", "deprels": "ADV", "no": 55}, {"word": "持有", "head": 61, "tag": "v", "deprels": "ATT", "no": 56}, {"word": "的", "head": 57, "tag": "u", "deprels": "RAD", "no": 57}, {"word": "金沙药业", "head": 61, "tag": "n", "deprels": "ATT", "no": 58}, {"word": "35.53%", "head": 61, "tag": "m", "deprels": "ATT", "no": 59}, {"word": "股权", "head": 54, "tag": "n", "deprels": "POB", "no": 60}, {"word": "，", "head": 54, "tag": "wp", "deprels": "WP", "no": 61}, {"word": "应当", "head": 73, "tag": "v", "deprels": "ADV", "no": 62}, {"word": "按照", "head": 73, "tag": "p", "deprels": "ADV", "no": 63}, {"word": "该", "head": 66, "tag": "r", "deprels": "ATT", "no": 64}, {"word": "股权", "head": 64, "tag": "n", "deprels": "POB", "no": 65}, {"word": "在", "head": 73, "tag": "p", "deprels": "ADV", "no": 66}, {"word": "购买", "head": 72, "tag": "v", "deprels": "ATT", "no": 67}, {"word": "日", "head": 68, "tag": "n", "deprels": "VOB", "no": 68}, {"word": "的", "head": 68, "tag": "u", "deprels": "RAD", "no": 69}, {"word": "公允", "head": 72, "tag": "a", "deprels": "ATT", "no": 70}, {"word": "价值", "head": 67, "tag": "n", "deprels": "POB", "no": 71}, {"word": "进行", "head": 10, "tag": "v", "deprels": "COO", "no": 72}, {"word": "重新", "head": 75, "tag": "d", "deprels": "ADV", "no": 73}, {"word": "计量", "head": 73, "tag": "v", "deprels": "VOB", "no": 74}, {"word": "，", "head": 4, "tag": "wp", "deprels": "WP", "no": 75}, {"word": "公允", "head": 78, "tag": "a", "deprels": "ATT", "no": 76}, {"word": "价值", "head": 85, "tag": "n", "deprels": "SBV", "no": 77}, {"word": "与", "head": 85, "tag": "p", "deprels": "ADV", "no": 78}, {"word": "其", "head": 82, "tag": "r", "deprels": "ATT", "no": 79}, {"word": "账面", "head": 82, "tag": "n", "deprels": "ATT", "no": 80}, {"word": "价值", "head": 84, "tag": "n", "deprels": "ATT", "no": 81}, {"word": "的", "head": 82, "tag": "u", "deprels": "RAD", "no": 82}, {"word": "差额", "head": 79, "tag": "n", "deprels": "POB", "no": 83}, {"word": "计", "head": 4, "tag": "v", "deprels": "VOB", "no": 84}, {"word": "入", "head": 85, "tag": "v", "deprels": "CMP", "no": 85}, {"word": "当期", "head": 86, "tag": "n", "deprels": "VOB", "no": 86}, {"word": "投资", "head": 86, "tag": "v", "deprels": "COO", "no": 87}, {"word": "收益", "head": 88, "tag": "n", "deprels": "VOB", "no": 88}], "sentence": "业绩修正原因说明根据《企业会计准则解释第4号》，公司通过多次交易，实现对非同一控制下的联营企业1广东嘉应制药股份有限公司2013年度业绩预告修正公告湖南金沙药业有限责任公司的合并，在合并报表中，对购买日之前持有的金沙药业35.53%股权，应当按照该股权在购买日的公允价值进行重新计量，公允价值与其账面价值的差额计入当期投资收益"}]